1 / 69

Cystic Fibrosis: Now a Multisystem Disease of Adolescence and Adulthood

Cystic Fibrosis: Now a Multisystem Disease of Adolescence and Adulthood. Andrew Bush MD FRCP FRCPCH Imperial School of Medicine & Royal Brompton Hospital. Email: a.bush@rbht.nhs.uk. CF: Multisystem, Adult Disease. How Has this come about? Late diagnosis of mild phenotypes

pembroke
Download Presentation

Cystic Fibrosis: Now a Multisystem Disease of Adolescence and Adulthood

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cystic Fibrosis: Now a Multisystem Disease of Adolescence and Adulthood Andrew Bush MD FRCP FRCPCH Imperial School of Medicine & Royal Brompton Hospital Email: a.bush@rbht.nhs.uk

  2. CF: Multisystem, Adult Disease • How Has this come about? • Late diagnosis of mild phenotypes • Effective modern treatment • What are the consequences? • Disease issues • Iatrogenic issues • Summary and Conclusions

  3. Late diagnosis of CF – 15%

  4. CF Diagnosis in Adolescence and Adult Life - 1 • Bronchiectasis, atypical asthma, chronic productive cough • Atypical ‘asthma’ • Male infertility • Acute pancreatitis • Non-tuberculous mycobacterial infection

  5. CF Diagnosis in Adolescence and Adult Life - 2 • Nasal polyps, sinusitis (but ASA) • Diabetes • Screening (diagnosis in a relative) • Pseudo-Bartter’s syndrome • Hepatomegaly, splenomegaly, variceal haemorrhage

  6. Sweat electrolytes - CF, normal, borderline

  7. What is the pick-up? 2 known mutations -69.7% 1 mutation found only - 23.7% No mutations found - 6.6% (N=10,998 genotyped, 21,976 alleles) What mutations are found? DF508 - 68.2% G542X - 2.3% G551D - 2.0% W1282X - 1.3% N1303K - 1.2% R553X - 0.9% CF Genotype (> 1000 Known Mutations)

  8. Nasal potentials – normal, CF, PBA treated CF: more negative baseline, bigger deflection on blocking ENaC, no response to low chloride/isoprenaline

  9. Other Helpful Pointers • Stool elastase – pancreatic status • Sputum culture – esp Staph. Aureus, Ps. Aeruginosa, B. Cepacia • HRCT Scan – Bronchiectasis • BAL – Neutrophilic lavage • Semen analysis – azoospermia

  10. 100 P. aeruginosa 80 60 Percent S. aureus 40 H. influenza B. cepacia 20 S. maltophilia 0 0 to 1 2 to 5 6 to 10 11 to 17 18 to 24 25 to 34 35 to 44 45+ Age Infection: Common CF Bugs

  11. CF: Oral antibiotics • Prophylaxis • Need more work • Avoid cephalosporins • Treatment • 2-4 weeks for any isolate of St aureus, H Influenza • Continuous therapy if repeated isolates

  12. Nebulized antibiotics: Indications • Eradication 1st isolates Ps aer • Colistin/Ciprofloxacin • Tobi ™ • Chronic Ps aer infection: Suppressive • Colistin • Aminoglycosides (TOBI, iv preparations) • Other

  13. Treatment of Ps Aeruginosa Proposed Protocol Step 1: (1st isolation) - 3/52 ciprofloxacin (25-50 mg/kg/day) and colistin 1mU, bd Step 2: (>1 isolation) - double dose colistin tds; ciprofloxacin; 3/52 therapy Step 3: (3rd isolation in 6/12) - as Step 3, 3/12 therapy (TOBI?) Pediatr Pulmonol 1997; 23: 330-5

  14. N=60 patients randomised to prn or 3 monthly ivabs prn – mean 3 course/yr Underpowered study IV Antibiotics: Treatment When? Deaths: 4 in regular group vs. 1 in prn Thorax 2000; 55: 355-8

  15. Home Equal N=58 patient study Infection 2002; 30: 387-91 N=51 paired treatments Eur Respir J 1994; 7: 1640-4 Hospital Better N=63 patient study Pediatr Pulmonol 1997; 24: 42-7 N=140 patient study #336 Audit of experience Ir J Med Sci 1999; 168: 25-8 Treatment Where?

  16. Cystic Fibrosis: Nutrition (1) • High fat, high calorie diet • Ensure adequate salt and fluid intake • Give fat soluble vitamins (A,E,D,K) • Monitor height, weight, BMI

  17. Cystic Fibrosis: Nutrition (2) • Pancreatic enzymes (amount, timing) • Acid reduction strategies if necessary (H2 blockers, PPIs) • PEG feeds as needed

  18. CF: Multisystem, Adult Disease • How Has this come about? • Late diagnosis of mild phenotypes • Effective modern treatment • What are the consequences? • Disease issues • Iatrogenic issues • Summary and Conclusions

  19. Did God do it, or was it the Dr? • Insulin deficiency/diabetes • Bone disease • Liver disease • Urogenital problems

  20. CF Insulinopaenia with Normal OGTT • Four CF patients, age 15-23 yrs • Normal OGTT, HbA1c • All had abnormal random blood glucose • Trial of 6-12 units/insulin/day Arch Dis Child 2002; 87: 430-1

  21. CF-related Glucose Intolerance: Mechanisms • N=18 OGTT, n=14 ivGTT, age 9-15 years • N=4 (20%) impaired glucose tolerance • N=9 (65%) had impaired insulin secretion • No correlation with nutritional status, Shwachman score or lung function Clin Endocrinol 2002; 56: 383-9 See also: Diabet Med 2002; 19: 221-6

  22. CF Insulopaenia: Prevalence • 335 CF patients; 9 diabetic (2.7%) • OGTT performed in 94, age 10-18, normal fasting glucose • 16/94 (17%) impaired glucose tolerance • 4/94 (4.3%) CFRD without fasting hyperglycaemia • Impaired GT only with PI, severe mutations J Pediatr 2003; 142: 128-32

  23. CF Insulopaenia: Consequences • CFRD is an adverse prognostic feature • Pediatr Pulmonol 2001; 32: 343-50 • Pediatr Pulmonol 2002; 33: 483-91 • Clinical deterioration may precede CFRD by 2-4 years • Eur J Pediatr 1992; 151: 684-7 • BlueJ 2000; 162: 891-5

  24. CF, Sugar and Insulin: Conclusions • Insulinopaenia not peripheral insulin resistance is the problem; insulin has important anabolic functions • Insulinopaenia is common; suspect in PI, severe mutations • Look for evidence of insulinopaenia in those with decline in nutrition or PFTs • Do not be deceived by a normal OGTT • The treatment of insulin deficiency/CFRD is insulin, not oral hypoglycaemics

  25. Dem Bones, Dem Bones..Dem Dry Bones • One third of adults have osteopaenia or a pathological fracture • Osteopaenia at best makes transplant more problematic

  26. CF Bone Disease: Risk Factors • Vit D, Vit K, Calcium malabsorption • Systemic inflammatory response • Lack of exercise (pathological, physiological) • Delayed puberty, hypogonadism • Inhaled and oral steroid therapy

  27. CF Bone Histomorphometry • N=20 CF adults • Iliac crest bone biopsies after double tetracycline labelling (n=19) Results • Low cancellous bone volume, due to low bone formation at tissue and cellular level BlueJ 2002; 166: 1470-4

  28. CF CF Normal Normal Normal and CF Bone biopsies

  29. CF: Change in BMD • Subjects: 114 CF adults and children, bone densitometry • Results: • Age < 24, decrease instead of increase • Age > 24, decrease instead of stability Results (n=114 adults) * * *significant decline in BMD, p<0.05 Thorax 2002; 57: 719-23

  30. Milk and Bones: Normal Adolescent Girls • Design: 18 month, open randomised trial in 82 girls • Subjects: extra pint of milk; controls, normal diet • Outcome: incl. BMD, bone mineral content BMJ 1997; 315: 1255-60 • Follow-up: changes still present 3.5 years later Lancet 2001; 358: 1208-12

  31. Pathology of CF liver disease • Mucus plugs cirrhosis • CFTR is expressed in apical membrane of cholangiocytes • CFTR controls fluid and electrolytes in bile • Secondary inflammation (cytokines and Oxygen radicals) • Modifier genes

  32. EpidemiologyRisk Factors • Meconium ileus: Odds Ratio 5.5 (3-11) • Male sex: Odds Ratio 2.5 (1.3-4.9) • “Severe mutations”: Odds Ratio 2.4 (1.2-4.8)

  33. EpidemiologyIncidence and prevalence • 177 patients followed for median 14yrs • CF Liver Disease defined as 2 of the following • Hepatomegaly • Abnormal liver enzymes • USS abnormalities (excluding fatty liver) • Cirrhosis defined on ultrasound scan

  34. Outcomes • 41% with no liver disease had abnormal liver enzymes • Those with CF Liver Disease wide range of abnormal enzymes (14% normal) • 48/177 developed CF Liver Disease. All<20yrs • 17 cirrhosis, 13 portal hypertension • 1 decompensation, 1 transplant • No overall effect on survival Colombo et al 2002

  35. Clinical features • Neonatal jaundice (not related to later cirrhosis) • Rarely a presenting feature (1.5%, USA) • Usually diagnosed due to abnormal enzymes, palpable liver and liver ultrasonography • Portal hypertension • Acute decompensation of cirrhosis (jaundice, ascites) • Biliary strictures (?)

  36. Regular assessment • Abdominal exam ?hepatosplenomegaly - every visit • Liver enzymes- annually • Ultrasound of abdomen- 2-3 yearly • Magnetic Resonance Imaging (MRI) cholangiography (specialist hepatologists)

  37. Portal Hypertension & Oesophageal Varices • No specific data for CF • Varices develop in almost all cirrhotics • Cause of death in 1/3 of cirrhosis • First bleed 20% mortality • Who to screen?

  38. Screening for varices • Who? – splenomegaly, low platelet count, spiders, all predictive but screen all with cirrhosis • When? • No varices – every 3 years • Small varices – every 2 years • Medium – treat and assess every 6-12 months

  39. Treatment for oesophageal varices (Drugs) • Beta-blockers – reduce incidence from 25% to 15% (40% Relative Risk reduction) • Isosorbide Mononitrate no effect • Beta-blockers + Isosorbide Mononitrate: ?? • Beta-blockers contraindicated in CF?

  40. Treatment for primary OVs(Interventional) • Sclerotherpy • Band ligation • First line therapy • 20% reduction in first bleed • 16% reduction in mortality • More effective than Beta-blocker

  41. Options for long term management • Repeated endoscopic treatment • Long term Beta- blockers • Surgical shunt or Transjugular intrahepatic shunt • Liver transplantation (not often best option for varices)

More Related